Unforeseen Structure Found in the Brains of Humans and Mice with Alzheimer’s Disease

Unforeseen Structure Found in the Brains of Humans and Mice with Alzheimer's Disease

New Insights into Alzheimer’s Disease

Alzheimer’s disease is the leading cause of dementia, currently affecting around 57 million individuals worldwide. This number is expected to climb to over 150 million by 2050.

This degenerative disorder is primarily marked by a buildup of beta-amyloid peptides and malformed tau proteins in the brain, ultimately resulting in neuron death and cognitive impairments.

Recently, researchers have begun investigating mitochondrial dysfunction as a significant factor in the development of Alzheimer’s disease. Mitochondria are often referred to as the cell’s powerhouses, so their malfunction is, well, quite concerning.

A study published in Nature Neuroscience has identified a new pathological element of the disease: mitochondrial plaques (MPs). This discovery, according to biochemist Paul Robbins from the University of Minnesota, highlights MPs as previously overlooked indicators of Alzheimer’s.

These MPs form due to ineffective mitophagy, the process through which the brain recycles its malfunctioning mitochondria.

Found in the brains of both genetically altered mice and humans with Alzheimer’s, these plaques consist of mitochondria at various degradation stages. Some are even ensnared in “cellular garbage bags” that either move or break them down.

Initial ultrastructural studies indicated high levels of damaged mitochondria in Alzheimer’s patients’ brains, but recent evidence shows that mitophagy is impaired in Alzheimer’s models.

Previous indirect assessments of mitophagy in Alzheimer’s mice didn’t provide a complete picture, largely due to sensitivity issues. To address this, researchers employed a “mitophagy reporter” called Keima, which is sensitive to pH levels and alters color with changes in acidity.

Using Keima, along with a set of proteins essential for mitochondrial function, the team discovered that MPs could be found either alone or alongside amyloid-beta aggregates, which are another characteristic feature of the disease.

As Alzheimer’s advances, these two types of aggregates become increasingly intermixed, possibly because MPs contain large amounts of amyloid precursor protein, the source of amyloid-beta peptides.

In the mouse models, MP aggregation began appearing around 15 weeks of age, reflective of early adulthood in humans. As age progressed, MP concentrations increased, leading to significant accumulation of acidic mitochondria by 50 to 60 weeks, indicating functionality loss in the brain’s recycling process.

One noteworthy observation was that MPs were not found in the brains of healthy age-matched controls, whether in mice or humans.

To better understand the manifestation of MPs, researchers stained the mice’s brains with a neuronal nuclear protein. Unlike amyloid plaques, which exist outside brain cells, these plaques seem to have a direct impact on neurons, presenting a new therapeutic target for Alzheimer’s treatment.

Interestingly, MPs were less often associated with neuronal cell bodies and more frequently found within neurites, which consist of the axons and dendrites that facilitate communication within the brain.

This accumulation of MPs seems to call upon lysosomes, the cell’s waste disposal units. However, the escalation of MP accumulation overwhelms this vital degradation process, leading to lysosome dysfunction. As a result, deteriorating mitochondria pile up in the brain.

Overall, these findings suggest that effective Alzheimer’s treatments may require addressing various sources of brain toxicity.

The researchers noted that while patients with Alzheimer’s who received treatments aimed at amyloid-beta were able to clear some plaques, this did not prevent ongoing neurodegeneration, possibly due to MPs affecting neuronal signaling pathways.

By deepening our understanding of how these plaques develop and their role in disease progression, researchers hope to uncover new strategies for slowing or even preventing Alzheimer’s.

The insights into MP accumulation might also point towards the potential for future therapies that target this process, like enhancing the functionality of lysosomes responsible for breakdown within cells. There’s even a chance that boosting mitophagy before it declines could become part of the solution.

Before concluding, it’s worth noting that stimulating mitophagy in Alzheimer’s mice has previously shown cognitive benefits, suggesting its importance in maintaining brain health and avoiding neurodegenerative issues.

Therefore, combining treatments that focus on both amyloid-beta plaques and mitochondrial plaques might lead to more effective therapies for Alzheimer’s disease.

This research has been published in Nature Neuroscience.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News